KIDS Earnings Prediction
The chart below shows how KIDS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KIDS sees a -1.51% change in stock price 10 days leading up to the earnings, and a +0.30% change 10 days following the report. On the earnings day itself, the stock moves by +0.20%. This data can give you a slight idea of what to expect for the next quarter's release.
KIDS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
KIDS Earnings Analysis
OrthoPediatrics Corp Corporation (KIDS.O) Earnings Conference Call
Positive
Earnings Per Share Beat: OrthoPediatrics Corp. reported a fourth quarter EPS of $-0.29, beating expectations of $-0.33.
Record Kids Served: In Q4 2024, OrthoPediatrics helped over 34,000 kids, a record high, contributing to over 138,000 kids for the full year, also a record.
Q4 Revenue Growth: The company achieved total revenue of $52.7 million in Q4 2024, representing a 40% growth compared to the same period last year.
T&D and Scoliosis Revenue Growth: The T&D business saw a 35% growth, while scoliosis revenue grew by 62% in Q4 2024, driven by strong domestic performance.
US Revenue Surge: US revenue increased by 52% to $42.9 million, representing 79% of total revenue, primarily due to market share gains across various product lines.
Adjusted EBITDA Surge: Adjusted EBITDA more than doubled to $3.0 million in Q4 2024 compared to $1.3 million in Q4 2023, and full-year adjusted EBITDA was $8.5 million, up from $5.0 million in the prior year.
2025 Revenue Projections: The company expects revenue for 2025 to be between $235 to $242 million, indicating a year-over-year growth of 15% to 18%.
EBITDA and Cash Flow Goals: OrthoPediatrics anticipates generating $15 million to $17 million in adjusted EBITDA in 2025, with a focus on achieving free cash flow positivity by Q4 2025.
OPSB Business Expansion: The company is expanding its OPSB business, which is generating a higher contribution margin than its implant business, leading to improved cash flows.
Strong International Growth: Internationally, despite some challenges, the company saw strong growth in non-LATAM T&D and scoliosis, with growth rates exceeding 20% and 30% respectively.
Negative
Global Sales Expansion Challenges: International sales growth was limited to 5% year-over-year, indicating challenges in expanding global market presence.
Restructuring Charge Impact: The company faced a restructuring charge of $3.7 million due to the closure of its Israel office, which may indicate operational difficulties.
Gross Profit Margin Decline: Gross profit margin decreased from 71% to 68% year-over-year, reflecting increased costs and adjustments in expense classifications.
Rising Operating Expenses: Operating expenses increased by 43% year-over-year, driven by restructuring charges and additional personnel costs, which could impact profitability.
Gross Margin Decline: The company anticipates a lower gross margin range of 72% to 73% for the upcoming years, down from previous expectations of 74% to 75%.
Free Cash Flow Challenges: Free cash flow usage was $3.7 million in Q4 2024, indicating ongoing cash flow challenges despite a reduction from previous quarters.
KIDS FAQs
How does KIDS typically perform around its earnings report dates?
Is OrthoPediatrics Corp (KIDS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KIDS Earning Call Sentiment
OrthoPediatrics Corp. (NASDAQ:KIDS) Q4 2024 Earnings Call Transcript
KIDS.O
0.96%Positive
The earnings call presented strong financial performance with a 40% revenue increase and EPS beat, despite a slight gross margin decline. Guidance was optimistic, with raised revenue expectations and positive free cash flow projected by 2025. The Q&A highlighted potential growth in Europe post-EU MDR approval and OPSB expansion. Despite some regulatory and economic challenges, the overall sentiment is positive, with strong growth and strategic plans in place. The lack of a share repurchase or dividend program slightly tempers the positive outlook, but the overall impact is expected to be positive in the short term.
